Perspectives
Integrated analysis confirms decision to remove Entresto® from UM
April 1, 2020Unique cost of care study on sacubitril-valsartan (sac-val) shows significant medical cost savings for adherent users; also, advanced analytics adds insights to impact UM for all users
Heart failure is the leading cause of death in the U.S. Sac-val is proven to decrease hospitalization and reduce death due to heart failure with reduced ejection fraction (HFrEF), also known as systolic heart failure.
As a knowledge management company, Prime wanted to study real world integrated benefits data on use of sac-val for adherent members, as well as all sac-val utilizing members.
This study looked at more than 1,000 members newly initiating sac-val. For an adherent members taking sac-val, after just one year:
- Medical costs decreased 38%
- Hospital costs decreased 69%
- Emergency room costs decreased 44%
- Total cost of care decreased 22%
When looking at the entire cohort (including adherent and nonadherent members), the cohort still showed a small total decrease in cost of care (2%). Prime’s recommendation to its health plan clients is to offer sac-val on an open formulary. Eliminating the prior authorization fast-tracks member access. This can save lives and health care costs.
Related news
Perspectives
July 25, 2024
Quarterly Drug Pipeline: July 2024
Clinical insights and competitive intelligence on anticipated drugs in development
Perspectives
July 22, 2024
Oncology Insights: 2024 ASCO Annual Meeting key findings
Findings from this year’s American Society of Clinical Oncology (ASCO) Annual Meeting will likely lead to clinical practice changes and U.S. Food and Drug Administration (FDA) drug approvals or expansions
Perspectives
July 16, 2024
LISTEN NOW: Beyond the business – Stories of corporate kindness | Pharmacy Friends Podcast
In this episode, we talk about how our employees' help goes beyond our work in health care, aiding in philanthropic efforts